• Evaluation of Complete Pathological Regression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients with BRCA1 Founder Mutation Aided Bayesian A/B Testing Approach.
    • Kedzierawski P, Macek P, Ciepiela I, Kowalik A, Gozdz S.
    • Diagnostics (Basel). 2021 Jun 23;11(7):E1144. doi: 10.3390/diagnostics11071144.
    • Letter to the editor regarding: 'Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis'.
    • Wang Y, van den Broek AJ, Schmidt MK.
    • Breast Cancer Res Treat.2021 Jun 16. doi: 10.1007/s10549-021-06289-2. Epub ahead of print.
    • Letter, Comment

    Review:

    Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis.

    • Clinical, radiometabolic and immunologic effects of olaparib in locally advanced triple negative breast cancer: the OLTRE window of opportunity trial.
    • Schettini F, Corona SP, Giudici F, Strina C, SIRICO M, Bernocchi O, Milani M, Ziglioli N, Aguggini S, Azzini C, Barbieri G, Cervoni V, Cappelletti MR, Molteni A, Lazzari MC, Ferrero G, Ungari M, Marasco E, Bruson A, Xumerle L, Zago E, Cerra D, Loddo M, Williams GH, Paris I, Scambia G, Generali D.
    • Front Oncol. 2021 Jun 11;10:686776. doi: 10.3389/fonc.2021.686776.
    • Study of the Genetic Variants in BRCA1/2 and Non-BRCA Genes in a Population-Based Cohort of 2155 Breast/Ovary Cancer Patients, Including 443 Triple-Negative Breast Cancer Patients, in Argentina.
    • Solano AR, Mele PG, Jalil FS, Liria NC, Podesta EJ, Gutiérrez LG.
    • Cancers (Basel). 2021 May 31;13(11):2711. doi: 10.3390/cancers13112711.
  • LitAlert ~~ GeneLit.com

    • Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer.
    • Elghazaly H, Rugo HS, Azim HA, Swain SM, Arun B, Aapro M, Perez EA, Anderson BO, Penault-Llorca F, Conte P, El Saghir NS, Yip CH, Ghosn M, Poortmans P, Shehata MA, Giuliano AE, Leung JWT, Guarneri V, Gligorov J, Gulluoglu BM, Aziz HA, Frolova M, Sabry M, Balch CM, Orecchia R, El-Zawahry HM, Al-Sukhun S, Karim KA, Kandil A, Paltuev RM, Foheidi M, El-Shinawi M, ElMahdy M, Abulkhair O, Yang W, Aref AT, Bakkach J, Eldin NB, Elghazawy H.
    • Cancers (Basel). 2021 May 8;13(9):2262. doi: 10.3390/cancers13092262.
    • Contralateral Prophylactic Mastectomy in Patients with Breast Cancer.
    • Chirurgia (Bucur). 2021 Mar-Apr;116(2 Suppl):73-83.
    • Chirurgia (Bucur). 2021 Mar-Apr;116(2 Suppl):73-83.
    • Functional consequences of a rare missense BARD1 c.403G>A germline mutation identified in a triple-negative breast cancer patient.
    • Zheng Y, Li B, Pan D, Cao J, Zhang J, Wang X, Li X, Hou W, Bao D, Ren L, Yang J, Wang S, Qiu Y, Zhou F, Liu Z, Zhu S, Zhang L, Qing T, Wang Y, Yu Y, Wu J, Hu X, Shi L.
    • Breast Cancer Res. 2021 May 1;23(1):53. doi: 10.1186/s13058-021-01428-5.
    • High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer.
    • Evans G, van Veen EM, Byers HJ, Evans SJ, Burghel GJ, Woodward ER, Harkness EF, Eccles DM, Greville-Haygate SL, Ellingford JM, Bowers NL, Pereira M, Wallace AJ, Howell SJ, Howell A, Lalloo F, Newman WG, Smith MJ.
    • J Med Genet. 2021 Mar 23:jmedgenet-2020-107347. doi: 10.1136/jmedgenet-2020-107347. Epub ahead of print.
    • Cisplatin +/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer.
    • Kalra M, Tong Y, Jones DR, Walsh T, Danso MA, Ma CX, Silverman P, King MC, Badve SS, Perkins SM, Miller KD.
    • NPJ Breast Cancer. 2021 Mar 22;7:29. doi: 10.1038/s41523-021-00240-w. eCollection 2021.